140 related articles for article (PubMed ID: 30507827)
1. The Explosion of a New Designer Drug, Flakka: Implications for Practice.
J Addict Nurs; 2018; 29(4):E16-E17. PubMed ID: 30507827
[No Abstract] [Full Text] [Related]
2. α-Pyrrolidinopentiophenone ("Flakka") Catalyzing Catatonia: A Case Report and Literature Review.
Richman EE; Skoller NJ; Fokum B; Burke BA; Hickerson CA; Cotes RO
J Addict Med; 2018; 12(4):336-338. PubMed ID: 29533309
[TBL] [Abstract][Full Text] [Related]
3. Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap.
İlhan B; Doğan H; Şahin EA; Karslıoğlu N; Koçak Ö
Am J Emerg Med; 2019 Mar; 37(3):562.e1-562.e3. PubMed ID: 30503281
[TBL] [Abstract][Full Text] [Related]
4. Miraa (catha edulis) as a cause of psychosis.
Dhadphale M; Mengech A; Chege SW
East Afr Med J; 1981 Feb; 58(2):130-5. PubMed ID: 6113948
[No Abstract] [Full Text] [Related]
5. Synthetic Stimulant Reaching Epidemic Proportions: Flakka-induced ST-elevation Myocardial Infarction With Intracardiac Thrombi.
Cherry SV; Rodriguez YF
J Cardiothorac Vasc Anesth; 2017 Feb; 31(1):e13-e14. PubMed ID: 27727084
[No Abstract] [Full Text] [Related]
6. [Khat--a new drug of abuse in Norway].
Al-Samarraie M; Khiabani HZ; Opdal MS
Tidsskr Nor Laegeforen; 2007 Mar; 127(5):574-6. PubMed ID: 17332809
[TBL] [Abstract][Full Text] [Related]
7. "Marvin, the Paranoid Android": The Case of an Alpha-PVP User in the Expanding Galaxy of NPS.
Pierluigi S; Laura B; Attilio N; Gurjeet K B; Gloria P; Davide M; Borgherini G; Giovanni M; Fabrizio S; Perini G; Ornella C
J Psychoactive Drugs; 2018; 50(4):306-313. PubMed ID: 29768112
[TBL] [Abstract][Full Text] [Related]
8. Reinforcing and discriminative-stimulus effects of two pyrrolidine-containing synthetic cathinone derivatives in rats.
Xu P; Lai M; Fu D; Liu H; Wang Y; Shen H; Zhou W
Pharmacol Biochem Behav; 2021 Apr; 203():173128. PubMed ID: 33515585
[TBL] [Abstract][Full Text] [Related]
9. [Psychiatric illness associated with amphetamines and other stimulants].
Fischer RB
Psychiatr Prax; 2000 May; 27(4):203. PubMed ID: 17195515
[No Abstract] [Full Text] [Related]
10. Beta-blocker use for toxicity from "bath salts".
Richards JR; Laurin EG; Albertson TE
J Emerg Med; 2015 Feb; 48(2):e45-6. PubMed ID: 25453853
[No Abstract] [Full Text] [Related]
11. The α- and β-Adrenergic Antagonist Controversy with Sympathomimetic Agents.
Banks ML; Worst TJ; Rusyniak DE; Sprague JE
J Emerg Med; 2015 Dec; 49(6):e209-10. PubMed ID: 26277195
[No Abstract] [Full Text] [Related]
12. Awash in a sea of 'bath salts': implications for biomedical research and public health.
Baumann MH
Addiction; 2014 Oct; 109(10):1577-9. PubMed ID: 24984975
[No Abstract] [Full Text] [Related]
13. [Khat-induced psychosis?].
Degraeve G
Tijdschr Psychiatr; 2007; 49(10):763-7. PubMed ID: 17929229
[TBL] [Abstract][Full Text] [Related]
14. DARK Classics in Chemical Neuroscience: α-Pyrrolidinovalerophenone ("Flakka").
Kolesnikova TO; Khatsko SL; Demin KA; Shevyrin VA; Kalueff AV
ACS Chem Neurosci; 2019 Jan; 10(1):168-174. PubMed ID: 30384587
[TBL] [Abstract][Full Text] [Related]
15. Naphyrone: a "legal high" not legal any more.
Vardakou I; Pistos C; Dona A; Spiliopoulou C; Athanaselis S
Drug Chem Toxicol; 2012 Oct; 35(4):467-71. PubMed ID: 22168347
[TBL] [Abstract][Full Text] [Related]
16. Acute psychosis induced by bath salts: a case report with clinical and forensic implications.
Stoica MV; Felthous AR
J Forensic Sci; 2013 Mar; 58(2):530-3. PubMed ID: 23317451
[TBL] [Abstract][Full Text] [Related]
17. Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine.
Gunderson EW; Kirkpatrick MG; Willing LM; Holstege CP
J Addict Med; 2013; 7(3):163-8. PubMed ID: 23732955
[TBL] [Abstract][Full Text] [Related]
18. "Bath salts"-induced psychosis and serotonin toxicity.
Joksovic P; Mellos N; van Wattum PJ; Chiles C
J Clin Psychiatry; 2012 Aug; 73(8):1125. PubMed ID: 22967774
[No Abstract] [Full Text] [Related]
19. The Growing Problem of New Psychoactive Substances (NPS).
Madras BK
Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
[TBL] [Abstract][Full Text] [Related]
20. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
